– Reuters
Sensei Biotherapeutics Presents New Preclinical Data On SNS-103 Targeting ENTPDase1 (CD39) At The American Association For Cancer Research Annual Meeting 2023
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today presented new preclinical data on its SNS-103